GNC’s CEO Mike Archbold says industry “should embrace, not fear, novel testing methods.”
Retailer GNC says the dietary supplement industry should welcome, not shun, the opportunity to use emerging test methods like DNA testing to bolster quality assurance. GNC’s statement follows last week’s news that the retailer has reached an agreement with New York Attorney General Eric Schneiderman (NY AG) in the course of the NY AG’s probe of GNC’s products and those of other dietary supplement retailers and manufacturers.
Industry members, as well as some scientists and DNA testing experts, have criticized the NY AG’s use of DNA testing on finished botanical extracts in his investigation, claiming that DNA testing is an inappropriate method for analyzing extract-form products. In its agreement with the NY AG, GNC agreed to further integrate DNA testing in its own quality-assurance process-an action largely criticized by the dietary supplements industry. In return, the NY AG agreed to cease its investigation of the GNC products.
In an open letter distributed today, GNC’s CEO, Mike Archbold, says, “As an industry, we should embrace, not fear, novel testing methods that provide additional opportunities to build customer trust.”
Archbold’s letter explains why the company chose to form an agreement with the NY AG. He states that a “protracted battle” with the NY AG would have been “counterproductive,” adding that the agreement underscores the purity, safety, and quality of the company’s investigated products and the fact that the NY AG’s investigation found no evidence that the GNC products do not meet FDA’s Good Manufacturing Practices (GMP) regulations.
As for GNC’s plans to adopt DNA testing, Archbold assures that while DNA testing will not replace the company’s existing test methodologies, adding the method will instead complement the company’s “robust” quality-assurance tools.
Archbold also mentions the promise that DNA testing may one day hold for the supplements industry. “DNA barcode testing may someday play a role in the identity testing of some source materials earlier in the production process. This will not in any way affect product quality for GNC’s products, but will provide even greater assurance of plant identity prior to extraction, which may help avoid the rejection of extracts later in the testing process.”
Also read:
DNA Testing Benefits May Be Silver Lining in NY AG/GNC Agreement, One Expert Says
DNA Experts Discuss What Makes Testing Difficult in NY AG Case
Editor: New York Attorney General Case Requires Strong Response, Supplement Leaders Say
Jennifer Grebow
Editor-in-Chief
Nutritional Outlook magazine jennifer.grebow@ubm.com
Photo © iStockphoto.com/ScantyNebula
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.